Drug Trial Radar · NCT03697304
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
211
Actual
Start
Mar 19, 2019
Primary completion
Dec 3, 2024
Study completion Dec 3, 2024
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Oct 5, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study in adults with various types of advanced cancer. The purpose of the study is to test a medicine called BI 754091 in combination with several other cancer medicines. BI 754091 is an immunotherapy. This means it may help the immune system fight cancer. Such therapies are also called immune checkpoint inhibitors. How long the participants are in the study depends on whether they benefit from treatment and whether they experience unacceptable side effects. The participants are put into different groups. Each group receives BI 754091 in combination with another medicine. The doctors check whether the tumors shrink or disappear. The doctors also check the general health of the participants.
Conditions
- Neoplasm Metastasis
- Advanced Tumors
- Metastatic Solid Tumors
Interventions
EzabenlimabDrug
240 mg of ezabenlimab (BI 754091), intravenously, on Day 1 of 21-day cycles.
BI 754111Drug
600 mg of BI 754111, intravenously, on Day 1 of 21-day cycles.
BI 836880Drug
720 mg of BI 836880, intravenously, on Day 1 of 21-day cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- [Module C] Objective Response (OR)Time frame: From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 188.3 weeks.
- [Module C] Objective Response (OR) - Bayesian Hierarchical ModelTime frame: From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 188.3 weeks.
- [Module A] Objective Response (OR)Time frame: From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 152.4 weeks.
- [Module A] Objective Response (OR) - Bayesian Hierarchical ModelTime frame: From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 152.4 weeks.
Locations
17 sites in 3 countries. Site status is shown where the registry gives one.
University of California San Diego
La Jolla, California
Florida Cancer Specialists-Fort Myers-52980
Fort Myers, Florida
Florida Cancer Specialists-Saint Petersburg-52979
St. Petersburg, Florida
Florida Cancer Specialists-Sarasota-61670
Tallahassee, Florida
Florida Cancer Specialists - East
West Palm Beach, Florida
Indiana University
Indianapolis, Indiana
Norton Cancer Institute
Louisville, Kentucky
Oklahoma University School of Community Medicine
Oklahoma City, Oklahoma
Tennessee Oncology
Chattanooga, Tennessee
Tennessee Oncology, PLLC-Nashville-52568
Nashville, Tennessee
Medical College Of Wisconsin
Milwaukee, Wisconsin
Cross Cancer Institute (University of Alberta)
Edmonton, Alberta, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
University College Hospital
London, United Kingdom
Guy's Hospital
London, United Kingdom
Sarah Cannon Research Institute, London
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.